Overview of Taris GemRIS, a Novel Drug Delivery System for Bladder Cancer.
| dc.contributor.author | Grimberg, Dominic C | |
| dc.contributor.author | Shah, Ankeet | |
| dc.contributor.author | Inman, Brant A | |
| dc.date.accessioned | 2020-06-01T21:20:22Z | |
| dc.date.available | 2020-06-01T21:20:22Z | |
| dc.date.issued | 2019-09-24 | |
| dc.date.updated | 2020-06-01T21:20:21Z | |
| dc.description.abstract | GemRIS, an implantable drug delivery system from Taris Biomedical that delivers continuous intravesical gemcitabine, shows potential for use in multiple bladder cancer settings. Ongoing and recently completed phase 1 trials in non-muscle-invasive as well as muscle-invasive bladder cancer are yielding promising preliminary results. | |
| dc.identifier | S2405-4569(19)30282-2 | |
| dc.identifier.issn | 2405-4569 | |
| dc.identifier.issn | 2405-4569 | |
| dc.identifier.uri | ||
| dc.language | eng | |
| dc.publisher | Elsevier BV | |
| dc.relation.ispartof | European urology focus | |
| dc.relation.isversionof | 10.1016/j.euf.2019.09.006 | |
| dc.title | Overview of Taris GemRIS, a Novel Drug Delivery System for Bladder Cancer. | |
| dc.type | Journal article | |
| duke.contributor.orcid | Grimberg, Dominic C|0000-0003-2289-4781 | |
| duke.contributor.orcid | Shah, Ankeet|0000-0001-5073-3016 | |
| duke.contributor.orcid | Inman, Brant A|0000-0002-6060-4485 | |
| pubs.organisational-group | School of Medicine | |
| pubs.organisational-group | Duke Cancer Institute | |
| pubs.organisational-group | Surgery, Urology | |
| pubs.organisational-group | Duke | |
| pubs.organisational-group | Institutes and Centers | |
| pubs.organisational-group | Surgery | |
| pubs.organisational-group | Clinical Science Departments | |
| pubs.organisational-group | Staff | |
| pubs.publication-status | Published |
Files
Original bundle
- Name:
- Overview of Taris GemRIS, a Novel Drug Delivery Sy.pdf
- Size:
- 384.09 KB
- Format:
- Adobe Portable Document Format
- Description:
- Accepted version